Good morning :)
Place Order
Add to Watchlist

Granules India Ltd

GRANULES

Granules India Ltd

GRANULES
Health CarePharmaceuticals
SmallcapWith a market cap of ₹13,161 cr, stock is ranked 465
Moderate RiskStock is 2.87x as volatile as Nifty
571.400.78% (+4.45)
571.400.78% (+4.45)

Price Chart

High
—
Low
—
Returns
—
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CarePharmaceuticals
SmallcapWith a market cap of ₹13,161 cr, stock is ranked 465
Moderate RiskStock is 2.87x as volatile as Nifty

How to use scorecard? Learn more

Health CarePharmaceuticals
SmallcapWith a market cap of ₹13,161 cr, stock is ranked 465
Moderate RiskStock is 2.87x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
27.024.080.28%
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
51.906.610.52%

Forecast & Ratings

Detailed Forecast 
100%
Analysts have suggested that investors can buy this stock

from 8 analysts

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Granules India Limited is a pharmaceutical company that manufactures finished dosages (FDs), pharmaceutical formulation intermediates (PFIs) and active pharmaceutical ingredients (APIs).

Investor Presentation

View older 

Nov 6, 2024

PDF
View Older Presentations

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Income

Balance Sheet

Cash Flow

Income Statement

Industry refers to the sub-sector this company belongs to.

Higher than Industry Revenue Growth

A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 13.88%, vs industry avg of 9.03%

Increasing Market Share

Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share increased from 1.07% to 1.2%

Lower than Industry Net Income

Net income is equal to net earnings (profit) less expenses. This number is an important measure of how profitable the company is

Over the last 5 years, net income has grown at a yearly rate of 11.38%, vs industry avg of 15.27%

Loading...

Financial YearFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024TTM
Total Revenue1,362.411,445.211,711.452,354.632,688.443,264.423,782.534,525.704,510.774,485.69
Raw Materialssubtract761.96679.96902.901,338.971,314.921,590.282,036.422,352.652,208.223,509.08
Power & Fuel Costsubtract34.9738.6748.2257.6859.7468.8574.6695.69100.64
Employee Costsubtract117.57140.19165.21209.82259.04324.29366.44420.35550.24
Selling & Administrative Expensessubtract145.21174.70216.04262.58313.30427.22521.25580.83696.63
Operating & Other expensessubtract21.2078.2173.8326.11126.33-28.3243.92148.5794.66
Depreciation/Amortizationsubtract58.4071.5176.20105.48136.95151.46158.63184.49207.33210.96
Interest & Other Itemssubtract37.0732.2633.0628.4627.0226.2823.2155.93105.82110.10
Taxes & Other Itemssubtract63.0365.2063.4089.11115.73154.90145.25170.58141.92168.39
EPS5.847.395.509.3113.1921.8916.6521.0816.7320.10
DPS0.650.901.001.001.001.501.501.501.501.50
Payout ratio0.110.120.180.110.080.070.090.070.090.07

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2022

Annual report

PDF

Investor Presentation

May 18PDF
Feb 8PDF
Nov 12PDF
Jul 27PDF
FY 2023

Annual report

PDF

Investor Presentation

May 16PDF
Jan 24PDF
Oct 20PDF
Aug 9PDF
FY 2024

Annual report

PDF

Investor Presentation

Aug 9PDF
FY 2025

Annual Report Pending

Investor Presentation

Nov 6PDF
 

Peers & Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Granules India Ltd32.474.080.28%
Sun Pharmaceutical Industries Ltd45.106.440.75%
Cipla Ltd29.414.520.87%
Torrent Pharmaceuticals Ltd68.5016.550.84%

Price Comparison

Compare GRANULES with any stock or ETF
Compare GRANULES with any stock or ETF
GRANULES
Loading...

Shareholdings

Promoter Holdings Trend

Decreased Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has decreased by 3.09%

Low Pledged Promoter Holding

Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Institutional Holdings Trend

Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding38.87%7.86%7.01%19.49%26.78%

Dec 2023

Mar 2024

Jun 2024

Sep 2024

Shareholding History

JunSepDec '23MarJunSep21.35%21.48%18.78%19.57%20.39%19.49%

Mutual Funds Holding Trend

Decreased Mutual Fund Holding

Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has decreased by 1.31%

Top 5 Mutual Funds holding Granules India Ltd




Funds (Top 5)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
Aditya Birla Sun Life Pure Value Fund - Growth - Direct Plan

Growth
1.1020%2.26%-0.17%50/92 (0)
Edelweiss Balanced Advantage Fund - Growth - Direct Plan

Growth
1.0819%1.16%1.09%81/151 (+22)
Axis India Manufacturing Fund - Growth - Direct Plan

Growth
0.6886%1.50%-0.09%49/93 (+3)

Compare 3-month MF holding change on Screener

Insider Trades & Bulk Deals

Loading...

smallcases

A smallcase is a basket of stocks/ETFs that represents an idea or theme.Diversify your risk and buy smallcases that have Granules India Ltd

Events

Dividend Trend

No Dividend Cuts

Dividends are the portion of earnings that a company distributes to all its shareholders every year

GRANULES has increased or maintained dividend levels over the last 5 years

Dividend Yield

Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation

Current dividend yield is 0.28%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹2.76 every year

Dividends

Corp. Actions

Announcements

Legal Orders

Upcoming Dividends

No upcoming dividends are available

Past Dividends

Cash Dividend

Ex DateEx DateJul 30, 2024

Final
Final | Div/Share: ₹1.50

Dividend/Share

₹1.50

Ex DateEx Date

Jul 30, 2024

Cash Dividend

Ex DateEx DateAug 3, 2023

Final
Final | Div/Share: ₹1.50

Dividend/Share

₹1.50

Ex DateEx Date

Aug 3, 2023

Cash Dividend

Ex DateEx DateJul 19, 2022

Final
Final | Div/Share: ₹0.75

Dividend/Share

₹0.75

Ex DateEx Date

Jul 19, 2022

Cash Dividend

Ex DateEx DateFeb 17, 2022

Interim 3
Interim 3 | Div/Share: ₹0.25

Dividend/Share

₹0.25

Ex DateEx Date

Feb 17, 2022

Cash Dividend

Ex DateEx DateNov 24, 2021

Interim 2
Interim 2 | Div/Share: ₹0.25

Dividend/Share

₹0.25

Ex DateEx Date

Nov 24, 2021

News & Opinions
Spotlight
Granules India drops after USFDA's 'OAI' status to Gagillapur unit

The United States Food and Drug Administration (USFDA) has further classified the inspection as 'Official Action Indicated' (OAI). The drug maker has responded to all the observations issued by the USFDA. Additionally, it has voluntarily undertaken a comprehensive evaluation of the facility for further enhancements that lead to improvement of the facility. 'The company will work with the US FDA on this activity and is confident that it will result in the US FDA approving the company's facility at Gagillapur in compliance with its expectations within a short time,' Granules stated in a regulatory filing. Granules India is primarily involved in the manufacturing and selling of active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates (PFIs), and finished dosages (FDs). Granules India consolidated net profit fell 4.79% to Rs 97.23 crore on 18.74% decline in total revenue from operations to Rs 966.62 crore in Q2 FY25 over Q2 FY24. Powered by Capital Market - Live

2 days agoCapital Market - Live
Spotlight
Granules India Ltd leads losers in 'A' group

C.E. Info Systems Ltd, Zen Technologies Ltd, Deepak Nitrite Ltd and Avalon Technologies Ltd are among the other losers in the BSE's 'A' group today, 03 December 2024.Granules India Ltd tumbled 9.44% to Rs 538.5 at 14:47 IST.The stock was the biggest loser in the BSE's 'A' group.On the BSE, 2.31 lakh shares were traded on the counter so far as against the average daily volumes of 83078 shares in the past one month.C.E. Info Systems Ltd crashed 8.22% to Rs 1550.5. The stock was the second biggest loser in 'A' group.On the BSE, 58968 shares were traded on the counter so far as against the average daily volumes of 8389 shares in the past one month.Zen Technologies Ltd lost 5.17% to Rs 1813.3. The stock was the third biggest loser in 'A' group.On the BSE, 27.18 lakh shares were traded on the counter so far as against the average daily volumes of 30586 shares in the past one month.Deepak Nitrite Ltd plummeted 5.05% to Rs 2617.75. The stock was the fourth biggest loser in 'A' group.On the BSE, 23267 shares were traded on the counter so far as against the average daily volumes of 28729 shares in the past one month.Avalon Technologies Ltd fell 4.67% to Rs 912. The stock was the fifth biggest loser in 'A' group.On the BSE, 32407 shares were traded on the counter so far as against the average daily volumes of 99736 shares in the past one month.Powered by Capital Market - Live

2 days agoCapital Market - Live
Spotlight
Granules India Ltd gains for third straight session

Granules India Ltd gained for a third straight session today. The stock is quoting at Rs 591.25, up 1.19% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.22% on the day, quoting at 24184. The Sensex is at 79872.83, up 0.09%. Granules India Ltd has gained around 7.51% in last one month. Meanwhile, Nifty Pharma index of which Granules India Ltd is a constituent, has gained around 0.69% in last one month and is currently quoting at 22240.2, up 1.08% on the day. The volume in the stock stood at 9.38 lakh shares today, compared to the daily average of 26.4 lakh shares in last one month. The benchmark December futures contract for the stock is quoting at Rs 595.1, up 1.48% on the day. Granules India Ltd is up 51.02% in last one year as compared to a 16.91% jump in NIFTY and a 38.53% jump in the Nifty Pharma index.The PE of the stock is 37.91 based on TTM earnings ending September 24.Powered by Capital Market - Live

3 days agoCapital Market - Live
Corporate
Granules India receives SBTi validation and approval for its net-zero goals

Granules India has received validation and approval from the Science Based Targets initiative (SBTi) for its near-term, long-term, and net-zero goals. These targets, aligned with the 1.5'C pathway, set Granules apart as one of the select Indian pharmaceutical companies with SBTi-validated targets under the initiative's new guidelines. Granules' goals are notable for their comprehensive scope and ambition. Granules India has committed to achieving net-zero greenhouse gas (GHG) emissions across its value chain, including all subsidiaries, by FY2050. In the near term, the company targets a 42% reduction in absolute Scope 1 and 2 emissions and Scope 3 emissions by FY2030, using FY2023 as the baseline, alongside transitioning to 100% renewable electricity. These near-term and long-term targets are aligned with the 1.5'C pathway, emphasizing Granules' dedication to ambitious climate action and achieving net-zero well before FY2050. Powered by Capital Market - Live

1 week agoCapital Market - Live
Spotlight
Granules India Andhra Pradesh facility gets EIR from USFDA

This US drug regulator conducted an inspection from 8 April to 12 April 2024. Now, the inspection is classified as 'No Action Indicated' (NAI), indicating compliance with current Good Manufacturing Practices (cGMP) standards and confirming that no further regulatory action is required. 'This outcome reflects the facility's high standards in the production of Active Pharmaceutical Ingredients (APIs) and Finished Dosages (FDs) for both oncology and non-oncology therapeutic areas,' said the drug regulator. During the inspection, the FDA conducted a comprehensive pre-approval inspection (PAI) and cGMP audit, which concluded with zero Form 483 observations. Krishna Prasad Chigurupati, chairman & managing director of Granules India said, The successful completion of this US FDA inspection with zero observations and the subsequent receipt of the EIR with NAI status reflects our unwavering commitment to maintaining the highest quality standards in our manufacturing operations. Granules India is primarily involved in the manufacturing and selling of Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation intermediates (PFIs) and Finished Dosages (FDs). Granules India consolidated net profit fell 4.79% to Rs 97.23 crore on 18.74% declined in total revenue from operations to Rs 966.62 crore in Q2 FY25 over Q2 FY24. Powered by Capital Market - Live

3 weeks agoCapital Market - Live
Earnings
Granules India consolidated net profit declines 4.79% in the September 2024 quarter

Net profit of Granules India declined 4.79% to Rs 97.23 crore in the quarter ended September 2024 as against Rs 102.12 crore during the previous quarter ended September 2023. Sales declined 19.48% to Rs 956.52 crore in the quarter ended September 2024 as against Rs 1188.00 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales956.521188.00 -19 OPM %21.2617.93 - PBDT180.91188.54 -4 PBT128.38136.02 -6 NP97.23102.12 -5 Powered by Capital Market - Live

4 weeks agoCapital Market - Live
Spotlight
Granules India gets USFDA nod for antidepressant tablets

Bupropion hydrochloride extended-release tablets USP (SR) is bioequivalent and therapeutically equivalent to wellbutrin SR sustained-release tablets, 100 mg, 150 mg, and 200 mg, by GlaxoSmithKline LLC. The approved ANDA is a widely prescribed medication for the treatment of major depressive disorder and for the prevention of seasonal affective disorder. The group now has a total of 67 ANDA approvals from the US FDA. Dr. Krishna Prasad Chigurupati, chairman and managing director, Granules India, said, This ANDA approval marks a significant milestone in our journey to expand Granules' presence in the U.S. market. Our continued focus on expanding our product portfolio in regulated markets like the U.S. ensures that we are meeting the growing healthcare needs of patients globally, while maintaining the highest standards of safety and efficacy.' Granules India is primarily involved in the manufacturing and selling of Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation intermediates (PFIs) and Finished Dosages (FDs). The pharma company reported a consolidated net profit of Rs 134.65 crore in Q1 FY25, steeply higher than Rs 47.89 crore posted in Q1 FY24. Revenue from operations in first quarter of FY25 was at Rs 1,179.87 crore, up 19.72% from Rs 985.52 crore reported in the same period a year ago. Shares of Granules India shed 0.19% to Rs 592.15 on the BSE.Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Granules India receives USFDA approval for Bupropion Hydrochloride ER Tablets USP

Granules India announced today that the U.S. Food & Drug Administration (USFDA) has approved the Abbreviated New Drug Application (ANDA) for Bupropion Hydrochloride Extended-Release Tablets USP (SR) 100 mg, 150 mg, and 200 mg filed by Granules Pharmaceuticals, Inc. (GPI), a wholly owned foreign subsidiary of the Company. Bupropion Hydrochloride Extended-Release Tablets USP (SR) are bioequivalent and therapeutically equivalent to Wellbutrin SR Sustained-Release Tablets, 100 mg, 150 mg, and 200 mg, by GlaxoSmithKline LLC. This is a widely prescribed medication for the treatment of major depressive disorder and for the prevention of seasonal affective disorder. Granules now has a total of 67 ANDA approvals from the US FDA.Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Granules India to announce Quarterly Result

Granules India will hold a meeting of the Board of Directors of the Company on 6 November 2024.Powered by Capital Market - Live

1 month agoCapital Market - Live
Spotlight
Granules India Ltd spurts 0.27%, gains for fifth straight session

Granules India Ltd is up for a fifth straight session today. The stock is quoting at Rs 605.5, up 0.27% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.69% on the day, quoting at 25137.7. The Sensex is at 82005.67, up 0.77%. Granules India Ltd has gained around 10.11% in last one month. Meanwhile, Nifty Pharma index of which Granules India Ltd is a constituent, has gained around 0.37% in last one month and is currently quoting at 23582.25, down 0.2% on the day. The volume in the stock stood at 25.12 lakh shares today, compared to the daily average of 46.32 lakh shares in last one month. The benchmark October futures contract for the stock is quoting at Rs 608.35, up 0.5% on the day. Granules India Ltd is up 71.77% in last one year as compared to a 27.4% jump in NIFTY and a 55.19% jump in the Nifty Pharma index.The PE of the stock is 32.51 based on TTM earnings ending June 24.Powered by Capital Market - Live

1 month agoCapital Market - Live